Fosamax Pre-Surgery Hold Window: What Surgeons and Patients Need to Know About Alendronate

Why the Pre-Surgery Hold Question Matters

Surgeons encounter alendronate-treated patients daily, yet the evidence base for pausing the drug before an operation is surprisingly thin. Alendronate is among the most prescribed medications in the United States, with an estimated 30 million bisphosphonate prescriptions dispensed annually according to CDC surveillance data. When a patient on long-term Fosamax needs a dental extraction, joint replacement, or jaw surgery, the clinician faces a genuine trade-off: the theoretical benefit of reduced osteonecrosis risk on one side, and the concrete fracture risk from stopping on the other.

The Pharmacokinetic Reality

Understanding alendronate's pharmacology is the starting point. After oral absorption, roughly 50% of the systemically available drug is taken up by bone within 24 hours and becomes incorporated into hydroxyapatite crystal [1]. The remainder is excreted renally unchanged. The skeletal half-life has been estimated at more than 10 years in humans, meaning that stopping alendronate does not appreciably change bone drug concentration in the weeks surrounding an elective procedure [2].

This long half-life is the central reason the American Association of Oral and Maxillofacial Surgeons (AAOMS) 2022 position paper concluded that a short-term drug holiday is unlikely to alter surgical healing in most patients [3].

Fracture Risk Does Not Disappear at the Surgical Admission Door

Patients prescribed alendronate have osteoporosis or significant osteopenia by definition. The Fracture Intervention Trial (FIT, N=2,027) demonstrated that alendronate 10 mg daily over 3 years reduced vertebral fracture risk by 47% compared with placebo (relative risk 0.53, 95% CI 0.41 to 0.68, P<0.001) [4]. Stopping that protection without an urgent reason exposes an already fragile skeleton to additional risk, particularly in the perioperative period when falls, immobility, and nutritional deficits compound baseline vulnerability.

Alendronate's Mechanism and Why It Complicates Surgical Healing

Alendronate is a nitrogen-containing bisphosphonate. It inhibits farnesyl pyrophosphate synthase (FPPS), an enzyme in the mevalonate pathway inside osteoclasts, causing osteoclast apoptosis and a net reduction in bone resorption [5]. This is precisely what makes it effective against osteoporotic fracture, and precisely what raises concern around surgeries that depend on new bone formation.

Suppression of Bone Remodeling

Normal fracture repair and osseointegration (relevant in dental implants and orthopedic fixation) require a remodeling cycle: osteoclast-driven resorption creates space that osteoblasts then fill with new bone. Prolonged bisphosphonate therapy blunts osteoclast activity, which may slow remodeling-dependent healing. A 2018 systematic review in the Journal of Dental Research found that implant failure rates in bisphosphonate-exposed patients were modestly higher than controls, though absolute differences remained small (approximately 3.6% vs 2.0%) [6].

Medication-Related Osteonecrosis of the Jaw (MRONJ)

MRONJ is the most clinically feared complication in this context. The condition is defined as exposed bone or bone that can be probed through a fistula in the maxillofacial region, present for more than 8 weeks in a patient receiving or previously exposed to antiresorptive therapy, without a history of radiation to the jaw [3].

For oral bisphosphonates, AAOMS estimates MRONJ incidence at 0.01% to 0.1% [3]. This is far lower than the 1 to 15% incidence seen with high-dose intravenous bisphosphonates used in oncology. Duration of oral bisphosphonate therapy longer than 4 years and concurrent corticosteroid use are the two strongest risk factors identified in observational data.

The Serum CTX Controversy

Some clinicians use serum C-terminal telopeptide (CTX) as a surrogate marker of bone turnover suppression before elective dental surgery, with a commonly cited threshold of 150 pg/mL as the minimum considered "safe" for extraction. The AAOMS 2022 position paper explicitly states that CTX "has not been validated as a reliable predictor of MRONJ risk" and no longer recommends its routine use in decision-making [3]. Clinicians who still order it should interpret results in the full clinical context, not as a binary green-light.

Current Guideline Recommendations on Holding Alendronate

No single authoritative body has issued a randomized-trial-backed universal hold window for alendronate before all surgery types. The guidance that exists is largely expert consensus.

AAOMS 2022 Position Paper

The AAOMS 2022 update states: "For patients who have been taking oral bisphosphonates for less than 4 years and have no clinical risk factors, no alteration or delay in the planned surgery is necessary." For patients on therapy longer than 4 years, or with concurrent corticosteroid use, a 2-month drug holiday before and after elective invasive procedures "may lower the risk of MRONJ," though the paper acknowledges direct evidence is absent [3].

This nuanced stance reflects a recognition that the drug's skeletal half-life makes brief holidays pharmacologically questionable while still giving clinicians a conservative framework.

American Society for Bone and Mineral Research (ASBMR) Drug Holiday Guidance

The ASBMR task force on long-term bisphosphonate therapy, published in the Journal of Bone and Mineral Research, recommends reassessing bisphosphonate need at 3 to 5 years for lower-risk patients (T-score above -2.5 at the hip after treatment) and at 6 years for higher-risk patients [7]. A drug holiday of 1 to 2 years is considered acceptable for lower-risk patients. This recommendation is disease-management oriented, not procedure-specific, but it provides the pharmacologic rationale that alendronate's residual skeletal effect persists for at least 1 to 2 years after stopping.

Orthopedic Surgery Context

For joint replacement and other orthopedic procedures, bisphosphonate use does not appear to compromise implant integration in the short term. A large registry study of 52,000 hip arthroplasty patients in Denmark found no significant difference in revision rates between bisphosphonate users and non-users at 10-year follow-up [8]. Routine pre-operative holds before orthopedic surgery are not endorsed by the American Academy of Orthopaedic Surgeons (AAOS).

The Fracture Risk Side of the Equation

Every conversation about holding alendronate must include a frank discussion of what stopping means for fracture risk.

Post-Discontinuation Bone Loss

A 2011 analysis of FLEX (Fracture Intervention Trial Long-Term Extension, N=1,099) showed that women who stopped alendronate after 5 years lost approximately 2.4% of femoral neck BMD over the subsequent 5 years, while those who continued lost only 0.6% [9]. The bone loss begins within 12 months of stopping. Hip fracture risk in the FLEX extension did not increase significantly in lower-risk women who paused, but vertebral fracture risk rose modestly.

Who Cannot Safely Pause

Patients with any of the following characteristics face meaningful fracture risk during even a short alendronate hold:

• Femoral neck T-score below -2.5 despite treatment
• Prior fragility fracture of the spine or hip
• Age above 75 years
• High falls risk combined with low BMD
• Concurrent systemic corticosteroid use at prednisone-equivalent doses of 7.5 mg/day or more

For these patients, the potential MRONJ benefit of a 2-month dental hold is outweighed by the fracture risk of stopping, and procedures should be planned around alendronate therapy rather than the reverse.

Shared Decision-Making Is Not Optional

The National Osteoporosis Foundation guidance (now incorporated into the Bone Health and Osteoporosis Foundation materials) states: "Treatment decisions should incorporate the patient's fracture risk, comorbidities, and preferences." Stopping a medication with a proven 47% vertebral fracture reduction [4] is a meaningful clinical action. Patients deserve a documented conversation about this trade-off before any hold is initiated.

A Practical Decision Framework for Clinicians

The following risk-stratified approach integrates current AAOMS, ASBMR, and AAOS guidance into a single clinical workflow. This framework was developed by the HealthRX medical team and is intended to supplement, not replace, individualized clinical judgment.

Step 1: Classify Procedure Risk

Low-risk procedures (simple dental fillings, non-surgical periodontal therapy, routine orthopedic injections): No hold required regardless of alendronate duration.

Moderate-risk procedures (single-tooth extraction, non-invasive orthopedic surgery, minor soft-tissue oral surgery): Proceed without a hold if alendronate duration is under 4 years and no corticosteroids. If duration exceeds 4 years, discuss optional 2-month hold with the prescribing physician.

High-risk procedures (multiple extractions, full-arch dental implants, major jaw surgery, bone grafting): Consult prescribing physician. For patients on alendronate fewer than 4 years with no risk factors, proceed with monitoring. For patients on alendronate 4 or more years or with corticosteroid use, a 2-month hold before and after surgery is reasonable if fracture risk allows.

Step 2: Calculate Fracture Risk Before Stopping

Use FRAX (fracturerisk.shef.ac.uk) to calculate 10-year hip and major osteoporotic fracture probability. If 10-year hip fracture probability exceeds 3% or major fracture probability exceeds 20%, do not hold alendronate without endocrinology or rheumatology input.

Step 3: Document the Decision

Record in the chart: indication for hold or continuation, FRAX score, procedure risk category, discussion of alternatives (for example, platelet-rich plasma to support healing), and follow-up plan to restart if held.

Step 4: Restart Timing

If a hold was implemented, restart alendronate once surgical site healing is confirmed at 6 to 8 weeks post-operatively. Delayed healing or MRONJ diagnosis requires continued hold and specialist referral.

What the Evidence Actually Shows About Pausing Before Dental Surgery

The clinical literature on MRONJ prevention through drug holidays is limited to retrospective series and expert consensus. No randomized controlled trial has demonstrated that a pre-surgical drug holiday reduces MRONJ incidence in oral bisphosphonate users.

A 2020 retrospective cohort study in Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology reviewed 194 patients who underwent tooth extraction while on oral bisphosphonates. MRONJ developed in 3 of 194 patients (1.5%), and all three had been on therapy for more than 5 years. None of the patients with holds shorter than 3 months showed reduced MRONJ incidence compared with those who continued therapy, consistent with the drug's pharmacokinetics [10].

A 2019 prospective observational study in the Journal of the American Dental Association of 1,319 dental extractions in bisphosphonate-exposed patients found that MRONJ occurred in 0.15% of cases and was not significantly associated with whether a drug holiday had been observed [11].

These findings do not prove that holds are useless for all patients. They do mean that the 2-month pause often recommended is based on biological plausibility, not direct outcome data showing harm reduction.

Alendronate Efficacy Context: Why This Drug Is Still the First-Line Choice

Before discussing when to hold alendronate, it helps to remember why it is prescribed. The FIT trial (N=2,027, published in JAMA 1998) remains foundational. Postmenopausal women with low bone density received alendronate 10 mg daily or placebo for 3 years. Alendronate reduced clinical vertebral fractures by 47% (RR 0.53, 95% CI 0.41 to 0.68) and non-vertebral fractures by 20% [4]. Hip fracture reduction of 51% was seen in a pre-specified subgroup with femoral neck T-score below -2.5 [4].

The drug's low cost, oral administration, and 20-plus years of post-marketing safety data make it the American College of Physicians' recommended first-line agent for women with osteoporosis who are at high fracture risk [12].

Long-Term Safety Profile

Concerns about atypical femoral fractures (AFF) and MRONJ emerged after widespread long-term use. The absolute risk of AFF increases with duration, reaching approximately 100 per 100,000 patient-years after 8 or more years of use according to a Swedish registry study (N=12,777) [13]. This is one reason the ASBMR recommends reassessing treatment need after 3 to 5 years rather than continuing indefinitely.

Dosing Reminders Relevant to Perioperative Management

The standard alendronate regimen is 70 mg once weekly. Patients must take it with 6 to 8 ounces of plain water, remain upright for at least 30 minutes, and delay food and other medications. In the perioperative period, if a patient is NPO (nil per os) on their scheduled dose day, the dose should simply be skipped and resumed the following week, as no evidence supports IV bridging with bisphosphonates.

Special Populations

Patients on Glucocorticoids

Glucocorticoid-induced osteoporosis is itself a separate indication for alendronate, with the American College of Rheumatology recommending bisphosphonates for patients taking prednisone 5 mg/day or more for 3 or more months at high fracture risk [14]. These patients face compounded risk: the underlying inflammatory disease, steroid-induced bone loss, and often immunosuppression that impairs wound healing. Hold decisions in this group require direct coordination between the prescribing rheumatologist, the surgeon, and, ideally, an endocrinologist.

Renal Impairment

Alendronate is contraindicated when estimated glomerular filtration rate (eGFR) is below 35 mL/min/1.73m². Patients in this range who are already on the drug perioperatively present a separate challenge: nephrotoxic anesthetic agents and IV contrast used in surgery may further compromise renal function. The perioperative team should review eGFR within 30 days of surgery and document whether alendronate is appropriate to continue.

Postmenopausal Women Under 65

Younger postmenopausal women on alendronate tend to have shorter cumulative exposure and lower MRONJ risk. For a 58-year-old woman on weekly alendronate for 2 years facing a single dental extraction, no hold is indicated by any current guideline. The procedure risk is low and her cumulative drug exposure is below the threshold where MRONJ risk becomes clinically meaningful.

Communicating the Hold Decision to Patients

Patients often encounter conflicting information. Their dentist may say stop the drug; their prescribing physician may say continue. A clear, written explanation helps. The conversation should cover:

1. What alendronate does for their bones (specific: 47% lower vertebral fracture risk from FIT [4])
2. Why a short pause does not change drug levels in bone (pharmacokinetics)
3. The low absolute MRONJ risk with oral bisphosphonates (0.01 to 0.1% [3])
4. The specific recommendation for their procedure and duration of use
5. When to restart if a hold is agreed upon

Patients who understand these points are more likely to adhere to a thoughtful plan and less likely to unilaterally stop their medication out of unfounded fear.

Monitoring After Surgery in Alendronate-Treated Patients

Post-operative follow-up for alendronate-treated patients should include wound check at 1 to 2 weeks, healing confirmation at 6 to 8 weeks, and documentation of alendronate restart date if it was held. Any exposed bone, pain, or delayed healing beyond 8 weeks should prompt referral to an oral and maxillofacial surgeon or bone specialist for MRONJ evaluation. Early-stage MRONJ (Stage 1: asymptomatic exposed bone only) can often be managed conservatively with chlorhexidine rinses and close monitoring without surgical debridement.